EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia

Natália Sudan Parducci, Maria Fernanda Lopes Carvalho, Isabelle Caroline Santos, Letícia Machado Favery Bertoline, Giovanna A. Castro, Juan Luiz Coelho-Silva, Tiago Agostinho Almeida, Peter Wipf, João Agostinho Machado-Neto

ACS Pharmacology & Translational Science · 03.11.2026

DOI: 10.1021/acsptsci.6c00373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 03.11.2026. Verfasst von Natália Sudan Parducci und 8 weiteren Autor:innen. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação de Amparo à Pesquisa do Estado de São Paulo, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) represents a critical focus for biomarker research, given its high mortality, rapid progression, substantial treatment resistance, and marked genetic heterogeneity. The present study identifies PTP4A3 as a relevant molecular determinant in the disease, linking its overexpression to adverse clinical outcomes, genomic instability, activation of oncogenic signaling pathways, and the expansion of poorly differentiated myeloid populations. The integration of in silico analyses with in vitro functional assays demonstrated that pharmacological inhibition of PTP4A3 significantly compromises leukemic cell viability and clonogenic potential, while promoting apoptotic signaling and reducing ERK1/2 phosphorylation in a time-dependent manner. The inhibitor JMS-053 showed consistent antileukemic activity across multiple AML cell models and displayed synergistic effects when combined with cytarabine, a cornerstone of current curative regimens. Collectively, these findings support the role of PTP4A3 as both a prognostic biomarker and a promising therapeutic target in AML, providing a rationale for further investigation of PTP4A3-targeted strategies in preclinical and clinical settings.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Parducci, N. S., Carvalho, M. F. L., Santos, I. C., Bertoline, L. M. F., Castro, G. A., Coelho-Silva, J. L., Almeida, T. A., Wipf, P., & Machado-Neto, J. A. (2026). Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia. ACS Pharmacology & Translational Science. https://doi.org/10.1021/acsptsci.6c00373

Vancouver

Parducci NS, Carvalho MFL, Santos IC, Bertoline LMF, Castro GA, Coelho-Silva JL, et al. Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia. ACS Pharmacology & Translational Science. 2026. doi:10.1021/acsptsci.6c00373

BibTeX
@article{Parducci2026,
  author = {Parducci, Natália Sudan and Carvalho, Maria Fernanda Lopes and Santos, Isabelle Caroline and Bertoline, Letícia Machado Favery and Castro, Giovanna A. and Coelho-Silva, Juan Luiz and Almeida, Tiago Agostinho and Wipf, Peter and Machado-Neto, João Agostinho},
  title = {Protein Tyrosine Phosphatase 4A3 (PTP4A3) as a Prognostic Biomarker and Pharmacological Target in Acute Myeloid Leukemia},
  journal = {ACS Pharmacology & Translational Science},
  year = {2026},
  doi = {10.1021/acsptsci.6c00373}
}
Kostenlos starten →